Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. May 1998; 77(9): 1502–1507.
PMCID: PMC2150202
Cell proliferation measured by MIB1 and timing of surgery for breast cancer.
L. S. Cooper, C. E. Gillett, P. Smith, I. S. Fentiman, and D. M. Barnes
Imperial Cancer Research Fund Clinical Oncology Unit, Guy's Hospital, London, UK.
We have investigated the use of the antibody MIB1 as a proliferative and prognostic marker in breast cancer and whether changes in proliferative activity could account for differences in prognosis of premenopausal women operated on during different phases of the menstrual cycle. MIB1 expression was strongly correlated with S-phase fraction and histological grade. There was no difference in MIB1 scores between different phases of the menstrual cycle. Both MIB1 score and timing of surgery correlated significantly with duration of survival, while the two together were even stronger predictors of overall survival. Women with slowly proliferating tumours surgically removed in the luteal phase had a very good prognosis, whereas women with rapidly proliferating tumours excised at other times of the cycle had a worse prognosis.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page.
Images in this article
Click on the image to see a larger version.
Articles from British Journal of Cancer are provided here courtesy of
Cancer Research UK